CLAIM CARD
The curated corpus on rapamycin's effects on immune and inflammatory outcomes comprises four studies with heterogeneous designs, populations, and effect directions (Wang 2022; Drion 2018; Ge 2023; Withers 2025). Study designs include one preclinical investigation (Drion 2018) and three observational cohorts (Wang 2022; Ge 2023; Withers 2025), with the latter enrolling adult populations. Duration and dosing vary considerably, ranging from nanofiber-based local delivery in a stent model (Wang 2022) to immunomodulatory rapamycin dosing in cancer vaccine trials (Withers 2025, NCT01536054). Reported effect directions span null (Wang 2022), mixed (Drion 2018; Ge 2023), and unclear (Withers 2025), indicating substantial heterogeneity in the evidence base.
Evidence grade: exploratory
Contradiction status: none
Publication: 1ece772b-d3e4-4ad0-b090-ac7e9ea4a1d6
Provenance: Derivation Web chain
Citation Support
source_1Mandrioli 2023source_2Lin 2022source_3Moel 2025source_4Gkioni 2025source_5Zhou 2024